PROTEO INC
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $205,992 | $199,293 | $242,930 | $826,099 | $544,653 |
| Operating income | −$245,212 | −$2,744 | −$71,061 | −$97,556 | −$474,179 | — |
| Net income | −$218,167 | $36,135 | −$145,231 | −$33,719 | −$311,968 | −$48,813 |
| Total assets | $238,437 | $253,951 | $270,312 | $349,446 | $574,581 | $1.1M |
| Total liabilities | $891,313 | $924,972 | $1.1M | $1.1M | — | — |
| Equity | −$652,876 | −$674,127 | −$865,797 | −$714,832 | −$655,635 | −$239,467 |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 24.9M | 23.9M | 23.9M | 23.9M | 23.9M | 23.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −12.3%
- Net margin
- −11.0%
- Return on equity
- 33.4%
- Return on assets
- −91.5%
- Return on capital (ROCE)
- −190.3%
- Liabilities / assets
- 373.8%
- Debt / equity
- —
- Book value / share
- $-0.03
- Revenue growth (YoY)
- 865.6%
- Net income growth (YoY)
- −703.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -141.37distress
- Accruals / assets
- 4.3%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2019
- NT 10-Qmissed a reporting deadline ↗May 15, 2018
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2018
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2017
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2014
- NT 10-Qmissed a reporting deadline ↗May 16, 2008
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Von Reden JorkDirector | Dec 12, 2018 | Grant | 1.0M | $0.08 |
| Paal Juergen Michael | Apr 15, 2016 | Buy | 20,000 | $0.08 |
| Paal Juergen Michael | Apr 24, 2015 | Buy | 2,500 | $0.25 |
| Paal Juergen Michael | Apr 13, 2015 | Buy | 1,359 | $0.10 |
| Paal Juergen Michael | Apr 9, 2015 | Buy | 2,500 | $0.10 |
| Paal Juergen Michael | Jan 13, 2015 | Buy | 50,000 | $0.09 |
| Paal Juergen Michael | Dec 21, 2014 | Buy | 1,110 | $0.08 |
| Paal Juergen Michael | Dec 15, 2014 | Buy | 24,281 | $0.08 |
| Paal Juergen Michael | Dec 8, 2014 | Buy | 14,619 | $0.08 |
| Wiedow Oliver MdDirector | Mar 19, 2014 | Gift | 4.3M | $0.00 |
| Bargmann BirgeDirector | Mar 19, 2014 | Gift | 4.3M | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Modified shareholder rights · Amended charter or bylawsJul 20, 2020
- Shareholder voteJul 10, 2020
- Other material eventMay 12, 2020
- Other material eventMar 30, 2020
- Entered a material agreement · Unregistered equity saleMar 3, 2020
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsApr 11, 2019
- Entered a material agreement · Unregistered equity saleDec 14, 2018
- Director / officer change · Other material eventNov 19, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13E3/ASCHEDULE 13E 3 AMENDMENTJul 22, 2020
- 15-12GFORM 15Jul 22, 2020
- 8-KFORM 8-KJul 20, 2020
- 8-KFORM 8-KJul 10, 2020
- 10-QFORM 10-QJun 5, 2020
- DEFA14ADEFINITIVE ADDITIONAL MATERIALSMay 26, 2020
- SC 13E3/AAMENDMENT TO SC 13E3May 26, 2020
- CORRESPMay 26, 2020
- DEFR14AREVISED NOTICE AND PROXY STATEMENTMay 26, 2020
- UPLOADMay 20, 2020
- DEF 14ADEFINITIVE PROXYMay 18, 2020
- 8-KFORM 8-KMay 12, 2020
- 10-K/AFORM 10-K/AMay 12, 2020
- SC 13E3SCHEDULE 13E-3May 7, 2020
- PRE 14APRELIMINARY PROXY STATEMENTMay 7, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.